We’ve been selected as a finalist in three categories at the 2026 SEHTA Healthcare Business Awards, recognizing VIOSync across Start-up, Partnership with the NHS, and Advances in Digital Healthcare.
The awards ceremony takes place on 23rd April 2026 at Scale Space, Imperial College London, bringing together the region’s leading healthtech companies, NHS trusts, academic institutions, and investors to celebrate excellence in healthcare innovation.
Three Finalist Categories
Start-up (Sponsored by Maidstone Innovation Centre)
This category recognizes early-stage companies demonstrating exceptional innovation, scalability potential, and commercial viability in healthcare technology.
Partnership with the NHS (Sponsored by City St George’s University of London)
This category evaluates collaborations between industry and NHS organizations that enhance service delivery, improve patient outcomes, or create innovative care pathways. Finalists demonstrate meaningful NHS engagement, deployment readiness, and measurable clinical impact.
Advances in Digital Healthcare (Sponsored by MedTecRec)
This category specifically evaluates how digital technologies enhance service delivery or create new ways of delivering healthcare. Assessment criteria include technologies employed, partnerships required for deployment, and improvements to patient care.
About the SEHTA Healthcare Business Awards
The Science and Engineering Health Technologies Alliance (SEHTA) awards are the leading regional celebration of collaborations between industry, academia, and the NHS. The awards cover one of the UK’s most innovation-dense healthcare regions, spanning Kent, Surrey, Sussex, Hampshire, Isle of Wight, London, Oxford, East of England, and Essex.
SEHTA supports health technology innovation from concept to commercialization, providing business support, regulatory guidance, and ecosystem connections to life science companies across the region. Managing Director Neil Roberts noted that 2026 saw record-breaking entries, with finalists representing the depth of achievement across the ecosystem.
Winners of SEHTA awards are automatically entered into the Medilink UK National Healthcare Business Awards, which will take place on 9th July 2026 in London, creating a pathway from regional recognition to national visibility.
Why Three Categories Matters
Being named a finalist in three distinct categories signals that VIOSync addresses multiple dimensions of healthcare innovation simultaneously:
- Start-up recognition validates that we’re building a commercially viable, scalable company, not just an interesting research project
- Partnership with the NHS confirms that we’re engaging meaningfully with the healthcare system we’re designed to serve, building relationships that enable real-world deployment
- Advances in Digital Healthcare acknowledges the technical innovation and clinical applicability of our AI platform
Most companies are recognized in one category. Being selected across three suggests that the judging panel sees VIOSync as addressing the full spectrum of what makes clinical AI deployable, technical capability, commercial viability, and healthcare system integration.
VIOSync: Earlier Recognition, Safer Responses
VIOSync is designed to support clinicians in recognizing sepsis and acute deterioration earlier through:
- Predictive Intelligence: Retrospective studies suggest the potential for sepsis risk prediction up to 48 hours in advance, depending on setting and data availability
- Explainable AI (XAI): Transparent outputs designed to support clinician trust, validation, and regulatory auditability
- Workflow Integration: Evidence-based guidance embedded directly into clinical workflows, reducing friction at the bedside
- Multimodal Data Fusion: Integrates vital signs, lab results, and clinical context using Digital Patient Twin architecture
The platform is currently completing CE MDR technical documentation with retrospective validation studies demonstrating clinical potential. We’re building VIOSync to be predictive (not reactive), explainable (not black-box), integrated (not another standalone dashboard), and evidence-ready (not pilot-forever).
NHS Partnership Recognition: What It Signals
The Partnership with the NHS category is particularly significant for a pre-market company. Clinical AI platforms often struggle with the gap between technical development and healthcare system integration, building impressive models that can’t actually deploy because they haven’t engaged with the complexities of NHS workflows, data infrastructure, procurement pathways, or clinical adoption.
Being recognized in this category validates that Aisthesis Medical is building VIOSync with NHS deployment in mind from the beginning, not as an afterthought once the technology is “finished”. This includes understanding clinical workflows, engaging with NHS stakeholders on validation requirements, and designing for integration with existing hospital systems.
Looking Ahead to 23rd April
We’ll be at Scale Space on 23rd April to represent VIOSync and connect with the healthcare innovation ecosystem that’s shaping the future of clinical AI deployment in the UK.
Whether we take home awards or not, being recognized as a finalist across three categories places us in conversation with the NHS trusts, academic institutions, investors, and industry leaders who will ultimately determine which clinical AI technologies move from promising research to deployed solutions.
Stay tuned for updates from the ceremony.
About Aisthesis Medical
Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven digital patient twin platform that goes beyond early sepsis prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.
Ready to Learn More?
If you’re a hospital, NHS trust, or healthcare investor interested in learning more about VIOSync or our security and compliance posture, we’d love to connect.
📩 Get in touch: https://aisthesismed.com/contact/
🌐 Learn more about VIOSync: https://aisthesismed.com/product/